The mTOR Signalling Pathway in Human Cancer

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

Repertoires of Autophagy in the Pathogenesis of Ocular Diseases

Li, Y., Jiang, Q. L., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,351 · see citing works

Autophagy in the Pathogenesis of Disease

Levine, B., & Kroemer, G. (2008) · Cell · doi:10.1016/j.cell.2007.12.018 · Cited by 7,069 · see citing works

Autophagy fights disease through cellular self-digestion

Mizushima, N., Levine, B., Cuervo, A. M., & Klionsky, D. J. (2008) · Nature · doi:10.1038/nature06639 · Cited by 6,452 · see citing works

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216 · see citing works

The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

Vivanco, I., & Sawyers, C. L. (2002) · Nature reviews. Cancer · doi:10.1038/nrc839 · Cited by 6,041 · see citing works

TOR signaling in growth and metabolism

Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · see citing works

<i>PTEN</i> , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785 · see citing works

Autophagy and Viruses: Adversaries or Allies?

Dong, X., & Levine, B. (2013) · Journal of Innate Immunity · doi:10.1159/000346388 · Cited by 4,441 · see citing works

Upstream and downstream of mTOR

Hay, N., & Sonenberg, N. (2004) · Genes &amp; Development · doi:10.1101/gad.1212704 · Cited by 4,181 · see citing works

TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival

Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914 · see citing works

AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint

Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849 · see citing works

Rapamycin fed late in life extends lifespan in genetically heterogeneous mice

Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · see citing works

Development by Self-Digestion

Levine, B., & Klionsky, D. J. (2004) · Developmental Cell · doi:10.1016/s1534-5807(04)00099-1 · Cited by 3,671 · see citing works

Anorexigenic and Orexigenic Hormone Modulation of Mammalian Target of Rapamycin Complex 1 Activity and the Regulation of Hypothalamic Agouti-Related Protein mRNA Expression

Watterson, K. R., Bestow, D., Gallagher, J. R., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2012) · Neurosignals · doi:10.1159/000334144 · Cited by 3,395 · see citing works

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · see citing works

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.

Kim, D.-H., Sarbassov, D., Ali, S. M., King, J. E., Latek, R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 3,135 · see citing works

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083 · see citing works

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha.

Alessi, D., James, S., Downes, C., Holmes, A. B., Gaffney, P., Reese, C., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 3,047 · see citing works

Defining the role of mTOR in cancer

Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833 · see citing works

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788 · see citing works

Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton

Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665 · see citing works

Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB

Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,659 · see citing works

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · see citing works

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551 · see citing works

Caloric Restriction Delays Disease Onset and Mortality in Rhesus Monkeys

Colman, R. J., Anderson, R. M., Johnson, S. C., Kastman, E. K., Kosmatka, K. J., Beasley, T. M., Allison, D. B., Cruzen, C., Simmons, H. A., Kemnitz, J. W., et al. (2009) · Science · doi:10.1126/science.1173635 · Cited by 2,277 · see citing works

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,097 · see citing works

Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome

Liaw, D., Marsh, D. J., Li, J., Dahia, P. L. M., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacoke, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-64 · Cited by 2,083 · see citing works

A mammalian protein targeted by G1-arresting rapamycin–receptor complex

Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053 · see citing works

Ras, PI(3)K and mTOR signalling controls tumour cell growth

Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · see citing works

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,010 · see citing works

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action.

Hara, K., Maruki, Y., Long, S., Yoshino, K., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., & Yonezawa, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00833-4 · Cited by 1,916 · see citing works

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes &amp; Development · doi:10.1101/gad.1110003 · Cited by 1,911 · see citing works

Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control

Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886 · see citing works

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803 · see citing works

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.

Vézina, C., KUDELSKI, A., & Sehgal, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,691 · see citing works

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677 · see citing works

Termination of autophagy and reformation of lysosomes regulated by mTOR

Yu, L., McPhee, C. K., Zheng, L., Mardones, G. A., Rong, Y., Peng, J., Mi, N., Zhao, Y., Liu, Z., Wan, F., et al. (2010) · Nature · doi:10.1038/nature09076 · Cited by 1,544 · see citing works

RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509 · see citing works

Ablation in Mice of the mTORC Components raptor, rictor, or mLST8 Reveals that mTORC2 Is Required for Signaling to Akt-FOXO and PKCα, but Not S6K1

Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,409 · see citing works

SIN1/MIP1 Maintains rictor-mTOR Complex Integrity and Regulates Akt Phosphorylation and Substrate Specificity

Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,407 · see citing works

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes &amp; Development · doi:10.1101/gad.1256804 · Cited by 1,384 · see citing works

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381 · see citing works

Phosphorylation and Functional Inactivation of TSC2 by Erk

Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268 · see citing works

Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function

Pause, A., Belsham, G. J., Gingras, A., Donzé, O., Lin, T.-A., Lawrence, J. C., & Sonenberg, N. (1994) · Nature · doi:10.1038/371762a0 · Cited by 1,242 · see citing works

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236 · see citing works

Dual Role of Phosphatidylinositol-3,4,5-trisphosphate in the Activation of Protein Kinase B

Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R. J., Reese, C. B., Painter, G. F., Holmes, A. B., McCormick, F. P., & Hawkins, P. T. (1997) · Science · doi:10.1126/science.277.5325.567 · Cited by 1,202 · see citing works

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202 · see citing works

Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin

Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186 · see citing works

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40

Haar, E. V., Lee, S.-I., Bandhakavi, S., Griffin, T. J., & Kim, D. (2007) · Nature Cell Biology · doi:10.1038/ncb1547 · Cited by 1,185 · see citing works

The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins

Harrington, L. S., Findlay, G. M., Gray, A., Толкачева, Т. А., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123 · see citing works

Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E

Fingar, D. C., Salama, S., Tsou, C., Harlow, E., & Blenis, J. (2002) · Genes &amp; Development · doi:10.1101/gad.995802 · Cited by 1,093 · see citing works

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,080 · see citing works

The LKB1 tumor suppressor negatively regulates mTOR signaling

Shaw, R. J., Bardeesy, N. M., Manning, B. D., Lopez, L. V., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,067 · see citing works

An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.

Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054 · see citing works

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR

Neshat, M., Mellinghoff, I., Tran, C., Stiles, B. L., Thomas, G., Petersen, R., Frost, P., Gibbons, J., Wu, H., & Sawyers, C. (2001) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.171076798 · Cited by 1,033 · see citing works

Rheb Binds and Regulates the mTOR Kinase

Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K., & Avruch, J. (2005) · Current Biology · doi:10.1016/j.cub.2005.02.053 · Cited by 1,005 · see citing works

Current development of mTOR inhibitors as anticancer agents

Faivre, S. J., Kroemer, G., & Raymond, É. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 998 · see citing works

Dysregulation of the TSC-mTOR pathway in human disease

Inoki, K., Corradetti, M. N., & Guan, K. (2004) · Nature Genetics · doi:10.1038/ng1494 · Cited by 970 · see citing works

GβL, a Positive Regulator of the Rapamycin-Sensitive Pathway Required for the Nutrient-Sensitive Interaction between Raptor and mTOR

Kim, D., Sarbassov, D. D., Ali, S. M., Latek, R. R., Guntur, K., Erdjument‐Bromage, H., Tempst, P., & Sabatini, D. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00114-x · Cited by 955 · see citing works

The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway

Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 922 · see citing works

Mutation of the PIK3CA Gene in Ovarian and Breast Cancer

Campbell, I., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 917 · see citing works

lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin

Nourse, J. L., Firpo, E. J., Flanagan, W. M., Coats, S., Polyák, K., Lee, M., Massagué, J., Crabtree, G. R., & Roberts, J. M. (1994) · Nature · doi:10.1038/372570a0 · Cited by 889 · see citing works

Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells

Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., & Abraham, R. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.815 · Cited by 887 · see citing works

Hierarchical phosphorylation of the translation inhibitor 4E-BP1

Gingras, A.-C., Raught, B., Gygi, S. P., Niedzwiecka, A., Miron, M., Burley, S. K., Polakiewicz, R. D., Wyslouch-Cieszynska, A., Aebersold, R., & Sonenberg, N. (2001) · Genes &amp; Development · doi:10.1101/gad.912401 · Cited by 883 · see citing works

Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression

Kunz, J., Henríquez, R., Schneider, U., Deuter‐Reinhard, M., Movva, N. R., & Hall, M. N. (1993) · Cell · doi:10.1016/0092-8674(93)90144-f · Cited by 838 · see citing works

Inappropriate Activation of the TSC/Rheb/mTOR/S6K Cassette Induces IRS1/2 Depletion, Insulin Resistance, and Cell Survival Deficiencies

Shah, O. J., Wang, Z., & Hunter, T. R. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.026 · Cited by 800 · see citing works

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

Chresta, C. M., Davies, B. R., Hickson, I., Harding, T. C., Cosulich, S. C., Critchlow, S. E., Vincent, J. P., Ellston, R. P. A., Jones, D., Sini, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 796 · see citing works

Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase

Nobukuni, T., Joaquin, M., Roccio, M., Dann, S. G., Kim, S. Y., Gulati, P., Byfield, M. P., Backer, J., Natt, F., Bos, J. L., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506925102 · Cited by 753 · see citing works

eIF-4E expression and its role in malignancies and metastases

Benedetti, A. D., & Graff, J. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207545 · Cited by 728 · see citing works

mSin1 Is Necessary for Akt/PKB Phosphorylation, and Its Isoforms Define Three Distinct mTORC2s

Frías, M. A., Thoreen, C. C., Jaffe, J. D., Schroder, W. A., Sculley, T. B., Carr, S. A., & Sabatini, D. M. (2006) · Current Biology · doi:10.1016/j.cub.2006.08.001 · Cited by 690 · see citing works

Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1

Um, S. H., D'Alessio, D., & Thomas, G. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.003 · Cited by 690 · see citing works

The Mammalian Target of Rapamycin (mTOR) Partner, Raptor, Binds the mTOR Substrates p70 S6 Kinase and 4E-BP1 through Their TOR Signaling (TOS) Motif

Nojima, H., Tokunaga, C., Eguchi, S., Oshiro, N., Sujuti, H., Yoshino, K., Hara, K., Tanaka, N., Avruch, J., & Yonezawa, K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200665200 · Cited by 678 · see citing works

The mRNA 5′ cap-binding protein eIF4E and control of cell growth

Sonenberg, N., & Gingras, A. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80150-6 · Cited by 673 · see citing works

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Heß, G., Herbrecht, R., Romaguera, J. E., Verhoef, G. E. G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F. C., Strahs, A. L., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641 · see citing works

Human eukaryotic translation initiation factor 4G (eIF4G) recruits Mnk1 to phosphorylate eIF4E

Pyronnet, S., Imataka, H., Gingras, A., Fukunaga, R., Hunter, T., & Sonenberg, N. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.270 · Cited by 639 · see citing works

IKKβ Suppression of TSC1 Links Inflammation and Tumor Angiogenesis via the mTOR Pathway

Lee, D., Kuo, H.-P., Chen, C., Hsu, J.-M., Chou, C., Wei, Y., Sun, H., Li, L., Ping, B., Huang, W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.05.058 · Cited by 639 · see citing works

Signaling Pathways and Molecular Mechanisms through which Branched-Chain Amino Acids Mediate Translational Control of Protein Synthesis

Kimball, S. R., & Jefferson, L. S. (2006) · Journal of Nutrition · doi:10.1093/jn/136.1.227s · Cited by 637 · see citing works

mTOR·RICTOR Is the Ser473 Kinase for Akt/Protein Kinase B in 3T3-L1 Adipocytes

Hresko, R. C., & Mueckler, M. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508361200 · Cited by 631 · see citing works

mTOR-targeted therapy of cancer with rapamycin derivatives

Vignot, S., Faivre, S. J., de Aguirre, & Raymond, É. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi113 · Cited by 613 · see citing works

Hypoxia-induced energy stress regulates mRNA translation and cell growth

Liu, L., Cash, T. P., Jones, R. G., Keith, B., Thompson, C. B., & Simon, M. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.010 · Cited by 607 · see citing works

The NF1 tumor suppressor critically regulates TSC2 and mTOR

Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., & Cichowski, K. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503224102 · Cited by 605 · see citing works

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine · doi:10.1038/nm1337 · Cited by 604 · see citing works

Deregulated Akt3 Activity Promotes Development of Malignant Melanoma

Stahl, J. M., Sharma, A. K., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M., KESTER, M. A., Sandirasegarane, L., & Robertson, G. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1399 · Cited by 595 · see citing works

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050008 · Cited by 593 · see citing works

The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis

Ruggero, D., Montanaro, L., Ma, L., Xu, W. G., Londei, P., Cordon‐Cardo, C., & Pandolfi, P. P. (2004) · Nature Medicine · doi:10.1038/nm1042 · Cited by 592 · see citing works

The TOR signaling cascade regulates gene expression in response to nutrientsPreprint

Cardenas, M. E., Cutler, N. S., Lorenz, M. C., Como, C. J. D., & Heitman, J. (1999) · Genes & Development · doi:10.1101/gad.13.24.3271 · Cited by 580 · see citing works

Identification of a Novel Hypoxia-Inducible Factor 1-Responsive Gene, <i>RTP801</i> , Involved in Apoptosis

Shoshani, T., Faerman, A., Mett, I., Zelin, E., Tenne, T., Gorodin, S., Moshel, Y., Elbaz, S., Budanov, A., Chajut, A., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2283-2293.2002 · Cited by 546 · see citing works

Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises

Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., & Workman, P. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.004 · Cited by 543 · see citing works

Regulation of ribosome biogenesis by the rapamycin-sensitive TOR-signaling pathway in Saccharomyces cerevisiae.

Powers, T., & Walter, P. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.4.987 · Cited by 540 · see citing works

Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity

Hahn-Windgassen, A., Nogueira, V., Chen, C.-C., Skeen, J. E., Sonenberg, N., & Hay, N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502876200 · Cited by 539 · see citing works

hVps34 Is a Nutrient-regulated Lipid Kinase Required for Activation of p70 S6 Kinase

Byfield, M. P., Murray, J. T., & Backer, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507201200 · Cited by 526 · see citing works

Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins

Hardwick, J. S., Kuruvilla, F. G., Tong, J. K., Shamji, A. F., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14866 · Cited by 523 · see citing works

PIK-Related Kinases: DNA Repair, Recombination, and Cell Cycle Checkpoints

Keith, C. T., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.270.5233.50 · Cited by 521 · see citing works

TOS Motif-Mediated Raptor Binding Regulates 4E-BP1 Multisite Phosphorylation and Function

Schalm, S. S., Fingar, D. C., Sabatini, D. M., & Blenis, J. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00329-4 · Cited by 512 · see citing works

Identification of a conserved motif required for mTOR signaling.

Schalm, S., & Blenis, J. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00762-5 · Cited by 507 · see citing works

mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availabilityPreprint

Mayer, C., Zhao, J., Yuan, X., & Grummt, I. (2004) · Genes & Development · doi:10.1101/gad.285504 · Cited by 506 · see citing works

The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2

Huang, J., Dibble, C. C., Matsuzaki, M., & Manning, B. D. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00289-08 · Cited by 504 · see citing works

Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein.

Peterson, R., Desai, B. N., Hardwick, J. S., & Schreiber, S. (1999) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.96.8.4438 · Cited by 496 · see citing works

The expanding TOR signaling network

Martin, D. E., & Hall, M. N. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.02.008 · Cited by 496 · see citing works

Rheb fills a GAP between TSC and TOR

Manning, B. (2003) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.09.003 · Cited by 483 · see citing works

PTEN signaling pathways in melanoma

Wu, H., Goel, V., & Haluska, F. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206451 · Cited by 482 · see citing works

mTOR-Dependent Regulation of Ribosomal Gene Transcription Requires S6K1 and Is Mediated by Phosphorylation of the Carboxy-Terminal Activation Domain of the Nucleolar Transcription Factor UBF†

Hannan, K., Brandenburger, Y., Jenkins, A., Sharkey, K., Cavanaugh, A., Rothblum, L., Moss, T., Poortinga, G., McArthur, G., Pearson, R., et al. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.23.8862-8877.2003 · Cited by 473 · see citing works

Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR

Yokogami, K., Wakisaka, S., Avruch, J., & Reeves, S. A. (2000) · Current Biology · doi:10.1016/s0960-9822(99)00268-7 · Cited by 468 · see citing works

Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma

Tsao, H., Yang, G., Goel, V., Wu, H., & Haluska, F. G. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22243.x · Cited by 467 · see citing works

Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance

Tremblay, F., Brûlé, S., Hee Um, S., Li, Y., Masuda, K., Roden, M., Sun, X. J., Krebs, M., Polakiewicz, R. D., Thomas, G., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706517104 · Cited by 465 · see citing works

Identification of Protor as a novel Rictor-binding component of mTOR complex-2

Pearce, L. R., Huang, X., Boudeau, J., Pawłowski, R., Wullschleger, S., Deák, M., Ibrahim, A. F. M., Gourlay, R., Magnuson, M. A., & Alessi, D. R. (2007) · Biochemical Journal · doi:10.1042/bj20070540 · Cited by 462 · see citing works

mTOR and cancer therapy

Easton, J. B., & Houghton, P. J. (2006) · Oncogene · doi:10.1038/sj.onc.1209886 · Cited by 460 · see citing works

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

García‐Martínez, J. M., Moran, J., Clarke, R. G., Gray, A., Cosulich, S. C., Chresta, C. M., & Alessi, D. R. (2009) · Biochemical Journal · doi:10.1042/bj20090489 · Cited by 459 · see citing works

Regulation of Peroxisome Proliferator–Activated Receptor-γ Activity by Mammalian Target of Rapamycin and Amino Acids in Adipogenesis

Kim, J. E., & Chen, J. (2004) · Diabetes · doi:10.2337/diabetes.53.11.2748 · Cited by 454 · see citing works

Regulation of mTOR and Cell Growth in Response to Energy Stress by REDD1

Sofer, A., Lei, K., Johannessen, C. M., & Ellisen, L. W. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.14.5834-5845.2005 · Cited by 449 · see citing works

Rapamycin and mTOR kinase inhibitors

Ballou, L. M., & Lin, R. Z. (2008) · Journal of Chemical Biology · doi:10.1007/s12154-008-0003-5 · Cited by 444 · see citing works

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin

Phung, T. L., Ziv, K., Dabydeen, D. A., Eyiah-Mensah, G., Riveros, M., Perruzzi, C. A., Sun, J., Monahan-Earley, R. A., Shiojima, I., Nagy, J. A., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.003 · Cited by 439 · see citing works

Targeting mTOR signaling for cancer therapy

Huang, S. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00071-7 · Cited by 436 · see citing works

Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycinPreprint

Oldham, S., Montagne, J., Radimerski, T., Thomas, G., & Hafen, E. (2000) · Genes & Development · doi:10.1101/gad.845700 · Cited by 430 · see citing works

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.

Yu, K., Toral‐Barza, L., Discafani, C. M., Zhang, W. G., Skotnicki, J. S., Frost, P., & Gibbons, J. J. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080249 · Cited by 421 · see citing works

The Immunosuppressant Rapamycin Mimics a Starvation-Like Signal Distinct from Amino Acid and Glucose Deprivation

Peng, T., Golub, T. R., & Sabatini, D. M. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5575-5584.2002 · Cited by 397 · see citing works

A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1

Özeş, O. N., Akça, H., Mayo, L. D., Gustin, J. A., Maehama, T., Dixon, J. E., & Donner, D. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051042298 · Cited by 383 · see citing works

HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway

Zhou, B. P., Hu, M. C. ‐., Miller, S. A., Yu, Z., Xia, W., Lin, S., & Hung, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.8027 · Cited by 371 · see citing works

Identification of a Proline-rich Akt Substrate as a 14-3-3 Binding Partner

Kovacina, K. S., Park, G. Y., Bae, S. S., Guzzetta, A. W., SCHAEFER, E. M., Birnbaum, M. J., & Roth, R. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210837200 · Cited by 361 · see citing works

Mechanism of action of the immunosuppressant rapamycin

Dumont, F. J., & Su, Q. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02233-3 · Cited by 357 · see citing works

Activity of rapamycin (AY-22,989) against transplanted tumors.

Eng, C. P., Sehgal, S. N., & Vézina, C. (1984) · The Journal of Antibiotics · doi:10.7164/antibiotics.37.1231 · Cited by 354 · see citing works

Prognostic relevance of the mTOR pathway in renal cell carcinoma

Pantuck, A. J., Seligson, D. B., Klatte, T., Yu, H., Leppert, J. T., Moore, L., O’Toole, T. E., Gibbons, J., Belldegrun, A. S., & Figlin, R. A. (2007) · Cancer · doi:10.1002/cncr.22677 · Cited by 351 · see citing works

M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase

Glantschnig, H., Fisher, J. E., Wesolowski, G., Rodan, G. A., & Reszka, A. A. (2003) · Cell Death &amp; Differentiation · doi:10.1038/sj.cdd.4401285 · Cited by 350 · see citing works

Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases

Raynaud, F. I., Eccles, S. A., Clarke, P. A., Hayes, A., Nutley, B. P., Alix, S., Henley, A. T., Di-Stefano, F., Ahmad, Z., Guillard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4615 · Cited by 350 · see citing works

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

Oza, A. M., Elit, L. M., Tsao, M., Kamel‐Reid, S., Biagi, J. J., Provencher, D. M., Gotlieb, W. H., Hoskins, P. J., Ghatage, P., Tonkin, K. S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1578 · Cited by 343 · see citing works

Tuberous Sclerosis: from Tubers to mTOR

Kwiatkowski, D. J. (2003) · Annals of Human Genetics · doi:10.1046/j.1469-1809.2003.00012.x · Cited by 340 · see citing works

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML

Zeng, Z., Sarbassov, D. D., Samudio, I. J., Yee, K. W. L., Munsell, M. F., Jackson, C. E., Giles, F. J., Sabatini, D. M., Andreeff, M., & Konopleva, M. Y. (2006) · Blood · doi:10.1182/blood-2006-06-030833 · Cited by 339 · see citing works

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Yu, K., Toral‐Barza, L., Shi, C., Zhang, W., Lucas, J., Shor, B., Kim, J., Verheijen, J. C., Curran, K. J., Malwitz, D. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0299 · Cited by 332 · see citing works

mTOR, translational control and human disease

Tee, A. R., & Blenis, J. (2005) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2004.11.005 · Cited by 320 · see citing works

Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells

Mondesire, W. H., Jian, W., Zhang, H., Ensor, J., Hung, M., Mills, G. B., & Meric‐Bernstam, F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0361 · Cited by 319 · see citing works

Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus

Bufalo, D. D., Ciuffreda, L., Trisciuoglio, D., Desideri, M., Cognetti, F., Zupi, G., & Milella, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2825 · Cited by 318 · see citing works

Prognostic Significance of Activated Akt Expression in Melanoma: A Clinicopathologic Study of 292 Cases

Dai, D. L., Martinka, M., & Li, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.168 · Cited by 318 · see citing works

Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis.

Bärlund, M., Forozan, F., Kononen, J., Bubendorf, L., Chen, Y.-D., Bittner, M. L., Torhorst, J., Haas, P., Bucher, C., Sauter, G., et al. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1252 · Cited by 305 · see citing works

Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?

Repasky, G. A., Chenette, E. J., & Der, C. J. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.09.014 · Cited by 299 · see citing works

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

Witzig, T. E., Reeder, C. B., LaPlant, B. R., et al. (2010) · Leukemia · doi:10.1038/leu.2010.226 · Cited by 299 · see citing works

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

Wolpin, B. M., Hezel, A. F., Abrams, T., Blaszkowsky, L. S., Meyerhardt, J. A., Chan, J. A., Enzinger, P. C., Allen, B., Clark, J. W., Ryan, D. P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9514 · Cited by 297 · see citing works

Determinants of Rapamycin Sensitivity in Breast Cancer Cells

Noh, W.-C., Mondesire, W. H., Peng, J., Jian, W., Zhang, H., Dong, J., Mills, G. B., Hung, M., & Meric‐Bernstam, F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0043 · Cited by 286 · see citing works

A novel AKT3 mutation in melanoma tumours and cell lines

Davies, M. A., Stemke‐Hale, K., Tellez, C. S., Calderone, T. L., Deng, W., Prieto, V. G., Lazar, A. J., Gershenwald, J. E., & Mills, G. B. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604637 · Cited by 273 · see citing works

Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.

Grünwald, V., deGraffenried, L. A., Russel, D., Friedrichs, W. E., Ray, R. B., & Hidalgo, M. M. (2002) · PubMed · Cited by 273 · see citing works

4E-Binding Protein 1: A Key Molecular “Funnel Factor” in Human Cancer with Clinical Implications

Armengol, G., Rojo, F., Castellví, J., Iglesias, C., Cuatrecasas, M., Pons, B., Baselga, J. M., & y Cajal, S. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0881 · Cited by 272 · see citing works

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma

Friedegund, M. (2005) · Frontiers in bioscience · doi:10.2741/1755 · Cited by 266 · see citing works

Regulation of translation elongation factor‐2 by insulin via a rapamycin‐sensitive signalling pathway.

Redpath, N. T., Foulstone, E. J., & Proud, C. G. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00582.x · Cited by 265 · see citing works

Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.

Geoerger, B., Kerr, K., Tang, C. B., Fung, K., Powell, B., Sutton, L. N., Phillips∥, P. C., & Janss, A. J. (2001) · PubMed · Cited by 263 · see citing works

The IκB kinase – a bridge between inflammation and cancer

Karin, M. (2008) · Cell Research · doi:10.1038/cr.2008.30 · Cited by 260 · see citing works

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

Ellard, S. L., Clemons, M. J., Gelmon, K. A., Norris, B. D., Kennecke, H. F., Chia, S., Pritchard, K. I., Eisen, A. F., Vandenberg, T. A., Taylor, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3033 · Cited by 259 · see citing works

Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression.

Dhawan, P., Singh, A. B., Ellis, D. L., & Richmond, A. J. (2002) · PubMed · Cited by 255 · see citing works

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

Liu, T.-J., Koul, D., LaFortune, T. A., Tiao, N., Shen, R., Maira, S.-M., Garcia-Echevrria, C., & Yung, W. K. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0160 · Cited by 254 · see citing works

The Principal Rapamycin-Sensitive p70s6k Phosphorylation Sites, T-229 and T-389, Are Differentially Regulated by Rapamycin-Insensitive Kinase Kinases

Dennis, P. B., Pullen, N., Kozma, S. C., & Thomas, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.11.6242 · Cited by 249 · see citing works

Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function

Jastrzebski, K., Hannan, K. M., Tchoubrieva, E. B., Hannan, R. D., & Pearson, R. B. (2007) · Growth Factors · doi:10.1080/08977190701779101 · Cited by 240 · see citing works

Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.

Tsao, H., Zhang, X., Fowlkes, K., & Haluska, F. G. (2000) · PubMed · Cited by 238 · see citing works

New insights into PTEN

Tamgüney, T., & Stokoe, D. (2007) · Journal of Cell Science · doi:10.1242/jcs.015230 · Cited by 234 · see citing works

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Herndon, J. E., Marcello, J. E., Norfleet, J. A., McLendon, R. E., Sampson, J. H., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9950-0 · Cited by 231 · see citing works

New Strategies in Estrogen Receptor–Positive Breast Cancer

Johnston, S. R. D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1823 · Cited by 230 · see citing works

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

Zhou, L., Huang, Y., Li, J., & Wang, Z. (2009) · Medical Oncology · doi:10.1007/s12032-009-9201-4 · Cited by 225 · see citing works

A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

Rizzieri, D. A., Feldman, E. J., DiPersio, J. F., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1372 · Cited by 225 · see citing works

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

Johnston, P. B., Inwards, D. J., Colgan, J. P., LaPlant, B. R., Kabat, B., Habermann, T. M., Micallef, I. N., Porrata, L. F., Ansell, S. M., Reeder, C. B., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21664 · Cited by 219 · see citing works

The RSK factors of activating the Ras/MAPK signaling cascade

Carriere, A. (2008) · Frontiers in bioscience · doi:10.2741/3003 · Cited by 218 · see citing works

Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (PKI-587), a Highly Efficacious Dual Inhibitor

Venkatesan, A. M., Dehnhardt, C. M., Santos, E. D., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901830p · Cited by 216 · see citing works

Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin

Huffman, T. A., Mothe‐Satney, I., & Lawrence, J. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022634399 · Cited by 215 · see citing works

Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer

Sato, T., Nakashima, A., Guo, L., Coffman, K., & Tamanoi, F. (2010) · Oncogene · doi:10.1038/onc.2010.28 · Cited by 214 · see citing works

The amino acid sensitive TOR pathway from yeast to mammals

Dann, S. G., & Thomas, G. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.04.068 · Cited by 213 · see citing works

Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors

Ballif, B. A., Roux, P. P., Gerber, S. A., MacKeigan, J. P., Blenis, J., & Gygi, S. P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409143102 · Cited by 211 · see citing works

United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling

Manning, B. D., & Cantley, L. C. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310573 · Cited by 211 · see citing works

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy

Morrow, P. K., Wulf, G. M., Ensor, J., Booser, D. J., Moore, J. A., Flores, P. R., Xiong, Y., Zhang, S., Krop, I. E., Winer, E. P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2321 · Cited by 209 · see citing works

Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells.

Grewe, M., Gansauge, F., Schmid, R. M., Adler, G., & Seufferlein, T. T. W. (1999) · PubMed · Cited by 209 · see citing works

The Mitogen-Activated Protein Kinase Signal-Integrating Kinase Mnk2 Is a Eukaryotic Initiation Factor 4E Kinase with High Levels of Basal Activity in Mammalian Cells

Scheper, G. C., MORRICE, N. A., Kleijn, M., & Proud, C. G. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.3.743-754.2001 · Cited by 202 · see citing works

Integrin (α6β4) regulation of eIF-4E activity and VEGF translation

Chung, J., Bachelder, R. E., Lipscomb, E. A., Shaw, L. M., & Mercurio, A. M. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200112015 · Cited by 202 · see citing works

Akt3 and Mutant V600EB-Raf Cooperate to Promote Early Melanoma Development

Cheung, M., Sharma, A. K., Madhunapantula, S. V., & Robertson, G. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5867 · Cited by 196 · see citing works

Therapeutic targets: MTOR and related pathways

Dancey, J. E. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.9.3175 · Cited by 195 · see citing works

Localization of Rheb to the endomembrane is critical for its signaling function

Buerger, C., DeVries, B., & Stambolic, V. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.03.220 · Cited by 192 · see citing works

Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin

Rini, B. I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4719 · Cited by 183 · see citing works

Mammalian TOR Controls One of Two Kinase Pathways Acting upon nPKCδ and nPKCε*

Parekh, D., Ziegler, W., Yonezawa, K., Hara, K., & Parker, P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34758 · Cited by 183 · see citing works

Lost in translation

Bjornsti, M., & Houghton, P. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.027 · Cited by 181 · see citing works

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)

Kreisl, T. N., Lassman, A. B., Mischel, P. S., Rosen, N. X., Scher, H. I., Teruya‐Feldstein, J., Shaffer, D. R., Lis, E., & Abrey, L. E. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9741-z · Cited by 176 · see citing works

Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells.

Seufferlein, T., & Rozengurt, E. (1996) · PubMed · Cited by 170 · see citing works

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors

Steelman, L. S., Navolanic, P. M., Sokolosky, M. L., Taylor, J. R., Lehmann, B. D., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Stadelman, K. M., Terrian, D. M., et al. (2008) · Oncogene · doi:10.1038/onc.2008.49 · Cited by 170 · see citing works

Alterations in VHL as potential biomarkers in renal-cell carcinoma

Gossage, L., & Eisen, T. G. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.42 · Cited by 167 · see citing works

Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma

Patel, P. H., Senico, P., Curiel, R. E., & Motzer, R. J. (2009) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2009.n.004 · Cited by 167 · see citing works

The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling

Basso, A. D., Mirza, A., Liu, G., Long, B. J., Bishop, W. R., & Kirschmeier, P. T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503763200 · Cited by 162 · see citing works

The genome and epigenome of malignant melanoma

Dahl, C., & Guldberg, P. (2007) · Apmis · doi:10.1111/j.1600-0463.2007.apm_855.xml.x · Cited by 161 · see citing works

First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting

Molckovsky, A., & Siu, L. L. (2008) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-1-20 · Cited by 159 · see citing works

Ras caught in another affair: the exchange factors for Ral

Wolthuis, R. M. F., & Bos, J. L. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80016-1 · Cited by 156 · see citing works

The complexes of mammalian target of rapamycin

Zhou, H., & Huang, S.-L. (2010) · Current protein and peptide science · doi:10.2174/138920310791824093 · Cited by 156 · see citing works

Regulation of Both Glycogen Synthase and PHAS-I by Insulin in Rat Skeletal Muscle Involves Mitogen-activated Protein Kinase-independent and Rapamycin-sensitive Pathways

Azpiazu, I., Saltiel, A. R., DePaoli-Roach, A. A., & Lawrence, J. C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.9.5033 · Cited by 152 · see citing works

Combined Inhibition of MAPK and mTOR Signaling Inhibits Growth, Induces Cell Death, and Abrogates Invasive Growth of Melanoma Cells

Lasithiotakis, K. G., Sinnberg, T. W., Schittek, B., Flaherty, K. T., Kulms, D., Maczey, E., Garbe, C., & Meier, F. E. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.44 · Cited by 149 · see citing works

RAPAMYCIN, A POTENT IMMUNOSUPPRESSIVE DRUG, CAUSES PROGRAMMED CELL DEATH IN B LYMPHOMA CELLS

Muthukkumar, S., Ramesh, T., & Bondada, S. (1995) · Transplantation · doi:10.1097/00007890-199508000-00010 · Cited by 145 · see citing works

Identification of S664 TSC2 Phosphorylation as a Marker for Extracellular Signal-Regulated Kinase–Mediated mTOR Activation in Tuberous Sclerosis and Human Cancer

Ma, L., Teruya‐Feldstein, J., Bonner, P., Bernardi, R., Franz, D. N., Witte, D. P., Cordon‐Cardo, C., & Pandolfi, P. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4798 · Cited by 145 · see citing works

Phosphatidic Acid Regulates Systemic Inflammatory Responses by Modulating the Akt-Mammalian Target of Rapamycin-p70 S6 Kinase 1 Pathway

Lim, H.-K., Choi, Y., Park, W., Lee, T., Ryu, S. H., Kim, S. Y., Kim, J.-R., Kim, J.-H., & Baek, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303789200 · Cited by 144 · see citing works

The PTEN–AKT3 signaling cascade as a therapeutic target in melanoma

Madhunapantula, S. V., & Robertson, G. P. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00585.x · Cited by 143 · see citing works

Elongation Factor-2 Kinase Regulates Autophagy in Human Glioblastoma Cells

Wu, H., Yang, J., Jin, S., Zhang, H., & Hait, W. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1554 · Cited by 143 · see citing works

PPARγ, 10 years later

Lazar, M. A. (2004) · Biochimie · doi:10.1016/j.biochi.2004.10.021 · Cited by 138 · see citing works

Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor.

Dilling, M. B., Dias, P., Shapiro, D. N., et al. (1994) · PubMed · Cited by 136 · see citing works

Genome‐wide lethality screen identifies new PI4,5P2 effectors that regulate the actin cytoskeleton

Audhya, A., Loewith, R., Parsons, A. B., Gao, L., Tabuchi, M., Zhou, H., Boone, C. M., Hall, M. N., & Emr, S. D. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600384 · Cited by 136 · see citing works

Rapamycin inhibits doxorubicin-induced NF-κB/Rel nuclear activity and enhances the apoptosis of melanoma cells

Romano, M. F., Avellino, R., Petrella, A., Bisogni, R., Romano, S., & Venuta, S. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.08.017 · Cited by 135 · see citing works

p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin.

Huang, S., Liu, L. N., Hosoi, H., Dilling, M. B., Shikata, T., & Houghton, P. J. (2001) · PubMed · Cited by 130 · see citing works

The Pleckstrin Homology Domain Proteins Slm1 and Slm2 Are Required for Actin Cytoskeleton Organization in Yeast and Bind Phosphatidylinositol-4,5-Bisphosphate and TORC2

Fadri‐Moskwik, M., Daquinag, A. C., Wang, S., Xue, T., & Kunz, J. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-07-0564 · Cited by 128 · see citing works

High Frequency of Submicroscopic Hemizygous Deletion Is a Major Mechanism of Loss of Expression ofPTENin Uveal Melanoma

Abdel‐Rahman, M. H., Yang, Y., Zhou, X.-P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2418 · Cited by 125 · see citing works

PRAS40 Deregulates Apoptosis in Malignant Melanoma

Madhunapantula, S. V., Sharma, A. K., & Robertson, G. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4234 · Cited by 124 · see citing works

Deregulated Ras signaling in developmental disorders: new tricks for an old dog

Schubbert, S., Bollag, G. E., & Shannon, K. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.004 · Cited by 116 · see citing works

The Roles of Autophagy in Cancer

Yun, C. W., & Lee, S. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113466 · Cited by 965 · see citing works

Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer

Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773 · see citing works

Rapalogs and mTOR inhibitors as anti-aging therapeutics

Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64099 · Cited by 531 · see citing works

Dysregulation of the IGF‐I/PI3K/AKT/mTOR signaling pathway in autism spectrum disorders

Chen, J., Alberts, I., & Li, X. (2014) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2014.03.006 · Cited by 151 · see citing works

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation

Esfahani, K., Al-Aubodah, T.-A., Thebault, P., Lapointe, R., Hudson, M., Johnson, N. A., Baran, D., Bhulaiga, N., Takano, T., Cailhier, J.-F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12628-1 · Cited by 109 · see citing works

Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer

Koustas, E., Karamouzis, M. V., Mihailidou, C., Schizas, D., & Papavassiliou, A. G. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.023 · Cited by 79 · see citing works

Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis

Head, S. A., Shi, W. Q., Yang, E. J., Nacev, B. A., Hong, S. Y., Pasunooti, K. K., Li, R.-J., Shim, J. S., & Liu, J. O. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b00849 · Cited by 82 · see citing works

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

Wang, B., Zhang, W., Zhang, G., Kwong, L., Lu, H., Tan, J., Sadek, N., Xiao, M., Zhang, J., Labrie, M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01911-5 · Cited by 66 · see citing works

mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i>

Morrow, J. J., Mendoza, A., Koyen, A., Lizardo, M. M., Ren, L., Waybright, T. J., Hansen, R. J., Gustafson, D. L., Zhou, M., Fan, T. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0326 · Cited by 27 · see citing works

Characterization of mTOR Activity and Metabolic Profile in Pediatric Rhabdomyosarcoma

Felkai, L., Krencz, I., Kiss, D. J., Nagy, N., Petővári, G., Dankó, T., Micsík, T., Khoor, A., Tornóczky, T., Sápi, Z., et al. (2020) · Cancers · doi:10.3390/cancers12071947 · Cited by 13 · see citing works

Lysosomal accumulation of mTOR is enhanced by rapamycin

Ohsaki, Y., Suzuki, M., Shinohara, Y., & Fujimoto, T. (2010) · Histochemistry and Cell Biology · doi:10.1007/s00418-010-0759-x · Cited by 22 · see citing works

Author response: Regulation of human mTOR complexes by DEPTOR

Wälchli, M., Berneiser, K., Mangia, F., et al. (2021) · doi:10.7554/elife.70871.sa2

Targeting mTOR globally in cancer: Thinking beyond rapamycin

Shor, B., Gibbons, J. J., Abraham, R. T., & Yu, K. (2009) · Cell Cycle · doi:10.4161/cc.8.23.10070 · Cited by 156 · see citing works

Endosomal docking of mTOR modulates mTORC1 activity

Melone, A. (2014) · edoc (University of Basel) · doi:10.5451/unibas-006266450

mTOR signaling in adipose tissue influences systemic lipid metabolism

Paolella, L. M., Tran, C. M., Chellappa, K., et al. (2018) · The FASEB Journal · doi:10.1096/fasebj.2018.32.1_supplement.536.8